Introduction
============

Thyroid cancer originates from parafollicular or follicular thyroid cells, and includes papillary thyroid cancer (PTC), anaplastic thyroid cancer, medullary thyroid cancer, poorly differentiated thyroid cancer and follicular thyroid cancer ([@b1-mmr-16-05-5954]). PTC accounts for 75--85% of all thyroid cancer cases and thus is the predominant thyroid cancer ([@b2-mmr-16-05-5954]). It often occurs in young females, and is the most common thyroid cancer in children and patients who have undergone radiation therapy to the head and neck ([@b3-mmr-16-05-5954]).

Research has focused on the pathogenesis of PTC. For instance, point mutation of serine-threonine protein kinase B-RAF (*BRAF*) occurs in approximately one-third to one-half of PTC cases, and *BRAF* can result in the activation of the carcinogenic mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase signaling pathway ([@b4-mmr-16-05-5954]). The *BRAF* mutation in PTC patients is associated with poorer clinicopathological outcomes and can be used to predict recurrence independently; therefore, the *BRAF* mutation may serve as a promising marker for risk assessment of PTC ([@b5-mmr-16-05-5954]--[@b7-mmr-16-05-5954]). Stephens *et al* ([@b8-mmr-16-05-5954]) investigated the loss of heterozygosity for three single nucleotide polymorphisms (SNPs; G691S, S904S, and L769L) of ret proto-oncogene (*RET*) in thyroid tumor and normal tissues, and demonstrated that *RET* SNPs may function in sporadic PTC. Salvatore *et al* ([@b9-mmr-16-05-5954]) demonstrated that both RET/PTC rearrangements and the *BRAF* mutation are markers of PTC and can be utilized for fine-needle aspiration in adjunction with traditional cytology. Vascular endothelial growth factor regulates cancer-associated neo-angiogenesis and progression, and its expression and polymorphisms may indicate the aggressiveness behavior of PTC ([@b10-mmr-16-05-5954]). The A-kinase anchoring protein 9-*BRAF* gene fusion, which is induced by the *BRAF* rearrangement through paracentric inversion of chromosome 7q, serves a role in activating the MAPK pathway in thyroid cancer ([@b11-mmr-16-05-5954]). However, the molecular mechanisms of PTC have not yet been fully investigated.

RNA-sequencing (RNA-seq), which is a useful tool for transcriptome analysis, can be applied to reveal genomic structural variations, gene fusion events, novel genes and transcripts ([@b12-mmr-16-05-5954],[@b13-mmr-16-05-5954]). By RNA-seq, Costa *et al* ([@b14-mmr-16-05-5954]) identified new missense mutations in Casitas B-cell lymphoma gene; *NOTCH1*; phosphoinositide-3-kinase regulatory subunit 4 and SW/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a, member 4 genes; somatic mutations in dicer 1, ribonuclease type III; met proto-oncogene (*MET*); and von Hippel-Lindau genes; and a new chimeric transcript induced by the WNK lysine deficient protein kinase 1-β1, 4-N-acetylgalactosaminyltransferase-3 gene fusion in PTC patients. Smallridge *et al* ([@b15-mmr-16-05-5954]) used RNA-seq to analyze differentially expressed genes (DEGs) between *BRAF* wild-type and *BRAF* V600E mutation PTCs, demonstrating that the *BRAF* V600E mutation inhibits expression of immune/inflammatory response genes but promotes expression of chemokine (C-X-C motif) ligand 14 and human leukocyte antigen-G. However, the above studies did not perform comprehensive bioinformatics analysis. In the present study, the transcriptional profiles of thyroid tumor tissues and adjacent normal tissues were obtained by RNA-seq. Thereafter, SNPs were identified and functionally annotated. In addition, the DEGs were screened and further investigated by enrichment analysis, protein domain analysis and protein-protein interaction (PPI) network analysis. Furthermore, the potential gene fusion events were separately predicted for the tumor tissues and normal tissues. The flow chart of the bioinformatics analysis is presented in [Fig. 1](#f1-mmr-16-05-5954){ref-type="fig"}.

Materials and methods
=====================

### Sample source and RNA sample preparation

Thyroid tumor tissues and adjacent normal tissues were collected from 5 PTC patients \[2 women and 3 men; mean age, 37.4 years; 3 patients in stage I (T1N1aM0) and 2 patients in stage III (T1N1aM0)\] from The Affiliated Hospital of Qingdao University (Qingdao, China). All patients were treated by thyroidectomy and lymphadenectomy; ultrasonography confirmed that the patients had no obvious abnormality after surgery. Total RNA was isolated from the tumor and normal tissues, using a TRIzol total RNA extraction kit (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA). The concentration of RNA was tested with Qubit^®^ RNA Assay kit in Qubit 2.0 Fluorometer (Thermo Fisher Scientific, Inc.). Next, the RNA integrity was assessed by spectrophotometry using NanoDrop™ 2000 (Thermo Fisher Scientific, Inc., Wilmington, DE, USA) at 260 and 280 nm and 1% (w/v) agarose gel electrophoresis at 37°C for 15 min with 95°C preheat for 5 min. The results were stained with ethidium bromide (0.50 µg/ml; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany), followed by visualization using the Agilent 2100 Bioanalyzer system (Agilent Technologies, Inc., Santa Clara, CA, USA). The following primers were used in this study: P5 (forward, AAT GAT ACG GCG ACC ACC GAG A and reverse, CAA GCA GAA GAC GGC ATA CGA G); P7 (forward, ATC TCG TAT GCC GTC TTC TGC TTG and reverse, CAA GCA GAA GAC GGC ATA CGA GAT). The Research Ethics Committee at The Affiliated Hospital of Qingdao University gave the approval for this study, and all participants wrote informed consent.

### cDNA library construction and Illumina RNA-seq

Library preparation and RNA-seq were performed by Beijing BerryGenomics Co., Ltd. (Beijing, China). Briefly, oligo(dT) magnetic beads were used to enrich mRNAs from total RNA, and then fragmentation buffer was applied to fragment the enriched mRNAs. Subsequently, the first cDNA strand was amplified using the mRNA templates and random hexamer primers. Subsequently, the second strand of cDNA was synthesized by adding DNA polymerase I (New England BioLabs, Inc., Ipswich, MA, USA), dNTPs (New England BioLabs, Inc.), RNase H (New England BioLabs, Inc.) and buffer. The double-stranded cDNA fragments were purified using QIAquick PCR Purification kit (Qiagen GmbH, Hilden, Germany) and eluted with elution buffer, followed by end repair and the ligation of sequencing adaptors. After the fragments with suitable size were selected by agarose gel electrophoresis, polymerase chain reaction (PCR) amplification was performed. Finally, the cDNA libraries were constructed and sequenced on an Illumina HiSeq 2500 platform according the manufacturer\'s protocol.

### Sequencing data processing

After removing low-quality reads (exceeding 50 bp and with \>50% of bases with Q-value ≤3) and those reads with \>3% (N bases) of adaptors or unknown nucleotides, the clean reads were obtained from the raw reads.

### SNP identification and DEG screening

The clean reads were mapped to the hg19 human reference genome by the Burrows-Wheeler Aligner ([bio-bwa.sourceforge.net/bwa.shtml](bio-bwa.sourceforge.net/bwa.shtml)) software ([@b16-mmr-16-05-5954]), and then SNPs were identified by the SAMtools software ([samtools.sourceforge.net](samtools.sourceforge.net)) ([@b17-mmr-16-05-5954]). Using ANNOVAR software (<http://www.openbioinformatics.org/annovar/>) ([@b18-mmr-16-05-5954]), functional annotation was performed for the identified SNPs to investigate their genomic locations and variation information.

The DEGs in the thyroid tumor tissues compared with the adjacent normal tissues were screened using edgR software ([bioconductor.org/packages/2.4/bioc/html/edgeR.html](bioconductor.org/packages/2.4/bioc/html/edgeR.html)) ([@b19-mmr-16-05-5954]). Based on the negative binomial model ([@b20-mmr-16-05-5954]), the gene significance levels between the two groups were calculated. Following this, the adjusted P-value (the false discovery rate, FDR) of each gene was calculated by the Benjamini-Hochberg method ([@b21-mmr-16-05-5954]). FDR\<0.05 and \|log~2~ fold-change (FC)\|≥1 were considered thresholds.

### Gene fusion analysis and enrichment analysis

The potential gene fusion events were predicted using FusionMap software (<http://www.omicsoft.com/fusionmap/>) ([@b22-mmr-16-05-5954]), and then visualized using Circos software (<http://www.circos.ca/>) ([@b23-mmr-16-05-5954]). The Gene Ontology (GO; [www.geneontology.org/](www.geneontology.org/)) database describes cellular component (CC), molecular function (MF), and biological process (BP) of gene products ([@b24-mmr-16-05-5954]). The Kyoto Encyclopedia of Genes and Genomes (KEGG; [www.genome.ad.jp/kegg/](www.genome.ad.jp/kegg/)) database, which consists of known genes and their functions, can be used for pathway mapping ([@b25-mmr-16-05-5954]). Using the Database for Annotation, Visualization and Integrated Discovery tool (DAVID; version 6.8; [david.abcc.ncifcrf.gov/](david.abcc.ncifcrf.gov/)) software ([@b26-mmr-16-05-5954]), GO functional and KEGG pathway enrichment analyses were conducted for the identified DEGs. P\<0.05 was considered as the cut-off criterion.

### PPI network analysis and protein domain analysis

The interactions among the proteins encoded by the DEGs were predicted using the Human Protein Reference Database (<http://www.hprd.org>) ([@b27-mmr-16-05-5954]), and then PPI network was visualized using Cytoscape software (version 3.2.0; [www.cytoscape.org/](www.cytoscape.org/)) ([@b28-mmr-16-05-5954]). Using pfam_scan tool (<http://www.ebi.ac.uk/Tools/pfa/pfamscan/>) ([@b29-mmr-16-05-5954]), the domains in the proteins containing risk SNP loci were predicted, and the domains in the proteins containing non-synonymous risk SNP loci were selected. In addition, the non-synonymous risk SNP loci in the interaction domains involved in the PPI pairs were identified using the Database of Protein Domain Interactions ([domine.utdallas.edu/cgi-bin/Domine](domine.utdallas.edu/cgi-bin/Domine)) ([@b30-mmr-16-05-5954]).

Results
=======

### SNP analysis

Upon mapping the clean reads to human reference genome hg19, 70,172 and 83,869 SNPs separately were identified in all of the thyroid tumor tissues and all of the adjacent normal tissues. A Venn diagram demonstrated that 18,795 SNPs were specific in the thyroid tumor tissues and were considered risk SNPs for PTC ([Fig. 2](#f2-mmr-16-05-5954){ref-type="fig"}). Subsequently, functional annotation was performed for these risk SNPs. Among the 18,795 SNPs, 739 risk SNPs were located in the exon regions ([Fig. 3A](#f3-mmr-16-05-5954){ref-type="fig"}). The variation information of the risk SNPs located in the exon regions is presented in [Fig. 3B](#f3-mmr-16-05-5954){ref-type="fig"}.

### Integrated analysis of SNPs and DEGs

With the thresholds of FDR\<0.05 and\|log~2~ FC\|≥1, a total of 2,686 DEGs were screened in the thyroid tumor tissues compared with adjacent normal tissues, including 1,361 upregulated genes and 1,325 downregulated genes. The integrated analysis of SNPs and DEGs demonstrated that 12,528 risk SNPs were located in 4,317 genes (157 upregulated genes and 519 downregulated genes).

Using the pfam_scan tool, the domains in the proteins containing risk SNP loci or non-synonymous risk SNP loci were predicted. The results demonstrated that the risk SNPs had no significant effects on protein domains, whereas the non-synonymous risk SNPs may affect protein domains. The non-synonymous risk SNPs in the protein domains are listed in [Table I](#tI-mmr-16-05-5954){ref-type="table"}.

### Gene fusion analysis

The potential gene fusion events were predicted and are presented in [Fig. 4](#f4-mmr-16-05-5954){ref-type="fig"}. A total of 11 and 4 gene fusion events were identified in all of the thyroid tumor tissues and all of the normal tissues, respectively. A total of three gene fusion events were predicted in both thyroid tumor tissues and normal tissues, including RNA binding motif protein (*RBM)*14-*RBM4*, NK2 homeobox 1-surfactant associated 3 (*NKX2-1-SFTA3*), and chromosome 1 open reading frame 86 (*C1orf86*)-*LOC100128003* gene fusions. The sodium channel, non-voltage gated 1 α-tumor necrosis factor receptor superfamily 1A gene fusion was predicted not in thyroid tumor tissues but in normal tissues. Furthermore, no gene fusion event was predicted in thyroid tumor tissues but not in normal tissues.

### Enrichment analysis of the DEGs containing risk SNPs

The DEGs containing risk SNPs were investigated by functional and pathway enrichment analyses. The upregulated genes containing risk SNPs were significantly enriched in urogenital system development (GO_BP, P=1.38×10^3^), extracellular region part (GO_CC, P=5.34×10^3^), hormone binding (GO_MF, P=7.23×10^3^), and pathways in cancer (pathway, P=1.28×10^2^) ([Table IIA](#tII-mmr-16-05-5954){ref-type="table"}). Meanwhile, the significant terms enriched for the downregulated genes containing risk SNPs included regulation of cell morphogenesis (GO_BP, P=4.41×10^9^), plasma membrane part (GO_CC, P-value = 2.22×10^11^), calcium ion binding (GO_MF, P=6.18×10^7^) and cell adhesion molecules (pathway, P=1.16×10^6^; [Table IIB](#tII-mmr-16-05-5954){ref-type="table"}).

### PPI network analysis

The PPI network constructed for the DEGs consisted of 716 nodes (273 upregulated genes and 443 downregulated genes) and 1,011 interactions ([Fig. 5](#f5-mmr-16-05-5954){ref-type="fig"}). Importantly, fibronectin 1 (*FN1*, degree=31) and transforming growth factor β (*TGFβ*) receptor 1 (*TGFβR1*, degree=22) had higher degrees in the PPI network. Thereafter, the non-synonymous risk SNP loci in the interaction domains involved in the PPI pairs were identified. A total of 7 PPI pairs containing the non-synonymous risk SNP loci in the interaction domains were identified ([Table III](#tIII-mmr-16-05-5954){ref-type="table"}). Particularly, the interaction domains involved in the interactions of *FN1* and 5 other proteins (such as tenascin C, *TNC*) contained non-synonymous risk SNP loci.

Discussion
==========

There were some limitations in the present study (low case number, no own *in vivo* or *in vitro* experiments), thus the findings in five PTC cases had the characteristics of an advanced case report. In this study, a total of 70,172 and 83,869 SNPs were identified in all of the thyroid tumor tissues and all of the normal tissues, respectively. A Venn diagram demonstrated that 18,795 risk SNPs were specific in the thyroid tumor tissues. There were more SNPs in the normal tissues than in the thyroid tumor tissues; however, only the 18,795 SNPs specific in the thyroid tumor tissues were potential risk SNPs for PTC. Total 2,686 DEGs were screened in the thyroid tumor tissues, including 1,361 upregulated genes and 1,325 downregulated genes. The integrated analysis of SNPs and DEGs demonstrated that 12,528 risk SNPs were located in 4,317 genes (157 upregulated and 519 downregulated genes).

A previous study demonstrated that the activity of the TGFβ/mothers against decapentaplegic (Smad)-dependent signaling pathway is associated with nodal metastasis, local invasion and *BRAF*-mutated PTCs ([@b31-mmr-16-05-5954]). *TGFβ1* has been identified as a key factor in PTC cells that affects the activation of stromal fibroblasts in a paracrine manner. Furthermore, the activation of the TGFβ/Smad3 and Notch signaling pathways can impact tumor growth ([@b32-mmr-16-05-5954]). Choe *et al* ([@b33-mmr-16-05-5954]) investigated the association between SNPs (−1444C/G, Asn389Asn, −834 G/A) of *TGFβR2* and PTC development, and the SNPs and clinicopathological characteristics of PTC (including lymph node metastasis, location, size, number and extrathyroidal invasion), and demonstrated that *TGFβR2* may serve a role in PTC progression in the Korean population. These studies suggested that *TGFβR* had a correlation with the pathogenesis of PTC. In the present study, *FN1* (degree=31) and *TGFβR1* (degree=22) had higher degrees in the PPI network. Thus, *TGFβR1* may serve an important role in the progression of PTC.

A total of 7 PPI pairs containing the non-synonymous risk SNP loci in the interaction domains were identified. Particularly, the interaction domains involved in the interactions of *FN1* and 5 other proteins (such as *TNC*) contained non-synonymous risk SNP loci. Prasad *et al* ([@b34-mmr-16-05-5954]) hypothesized that an immunohistochemical panel containing *FN1*, Hector Battifora mesothelial cell 1 and galectin-3 may contribute to the diagnosis of thyroid tumors derived from follicular cells. Using reverse transcription-quantitative polymerase chain reaction, da Silveira Mitteldorf *et al* ([@b35-mmr-16-05-5954]) demonstrated that *FN1*, *MET*, glutaminyl-peptide cyclotransferase, and UDP-galactose-4-epimerase were significantly upregulated in patients with PTC. *TNC* re-expression can be detected by immunohistochemistry in papillary and medullary thyroid carcinomas supplemented by the analysis of two *TNC* mRNA splice variants; thus *TNC* may be synthesized by tumor cells ([@b36-mmr-16-05-5954]). The above studies indicated that *FN1* is involved in PTC, and *TNC* is also associated with tumor. Therefore, *FN1* and *TNC* containing the non-synonymous risk SNP loci might serve a role in PTC by interacting with each other.

Furthermore, 11 and 4 gene fusion events were identified in all of the thyroid tumor tissues and all of the normal tissues, respectively. A total of three gene fusion events were predicted in both normal tissues and thyroid tumor tissues, including *RBM14-RBM4*, *NKX2-1-SFTA3* and *C1orf86-LOC100128003* gene fusions. Through *NKX2-1* and forkhead box E1 (*FOXE1*) genotyping, Matsuse *et al* ([@b37-mmr-16-05-5954]) revealed that both *NKX2-1* and *FOXE1* can increase the risk of Japanese sporadic PTC. The missense mutation (1016C\>T) in homeobox transcription factor *TTF1* (*TITF-1*)*/NKX2-1* is the first germline mutation detected in multinodular goiter (MNG)/PTC patients, which increases the susceptibility for PTC and/or MNG and contributes to the development of PTC ([@b38-mmr-16-05-5954],[@b39-mmr-16-05-5954]). Impaired paired box 8 and *TITF-1/NKX2*-action may be correlated with the expression changes of type 1 and type 2 iodothyronine 5′ deiodinases in PTC ([@b40-mmr-16-05-5954]). *NKX2-1* is important for thyroid organogenesis and controls thyroid functions, and its inactivation is implicated in epigenetics in thyroid carcinomas; thus, *TTF-1* may serve as a therapeutic target via epigenetic modification ([@b41-mmr-16-05-5954]). These previous studies demonstrated that *NKX2-1* also acted in the mechanisms of PTC. Therefore, the *NKX2-1-SFTA3* gene fusion might be involved in PTC. However, small sample size, as well as the lack of experimental validation and the basic molecular analysis of *RAS* and *BRAF* status were the limitations of the present study. Furthermore, the definitive pathophysiological role and underlying mechanism of the *TGFβR1/NKX2-1-SFTA3* gene fusion as well as non-synonymous risk SNP loci of *FN1* and *TNC* in PTC remain unclear. Thus, further confirmation of these results is required.

In conclusion, the current study compared the transcriptional profiles of thyroid tumor tissues and normal tissues. A total of 18795 risk SNPs and 2686 DEGs were identified in the thyroid tumor tissues. Therefore, *TGFβR1* and the *NKX2-1-SFTA3* gene fusion might be implicated in PTC. Additionally, *FN1* and *TNC* containing the non-synonymous risk SNP loci might serve a role in PTC by interacting with each other.

The present study was supported by the Qingdao Municipal Science and Technology Bureau (grant no. 13-1-4-166-jch).
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###### 

Non-synonymous risk SNPs in the protein domains.

  Gene           AA Change   SNP id      Domain start   Domain end   Hmm acc      Hmm name
  -------------- ----------- ----------- -------------- ------------ ------------ ------------------
  *CSGALNACT1*   S193N       rs7017776     168            507        PF05679.13   CHGN
  *IYD*          C265R       rs612421        98           267        PF00881.21   Nitroreductase
  *ITGA7*        R655H       rs1800974     515          1,006        PF08441.9    Integrin_alpha2
  *TMEM171*      R86G        rs637450          2          319        PF15471.3    TMEM171
  *TMEM171*      N139K       rs636926          2          319        PF15471.3    TMEM171
  *AGT*          M268T       rs699         114            481        PF00079.17   Serpin
  *ATP11A*       M317V       rs368865      100            377        PF00122.17   E1-E2_ATPase
  *CDT1*         C234R       rs507329      186            350        PF08839.8    CDT1
  *CDT1*         T262A       rs480727      186            350        PF08839.8    CDT1
  *CENPF*        N3106K      rs7289      3,061          3,109        PF10490.6    CENP-F_C\_Rb_bdg
  *COL1A1*       T1075A      rs1800215   1,019          1,077        PF01391.15   Collagen
  *EBI3*         V201I       rs4740        130            209        PF00041.18   fn3
  *FN1*          T817P       rs2577301     812            889        PF00041.18   fn3
  *HES4*         R44S        rs2298214       35             91       PF00010.23   HLH
  *LCP1*         K533E       rs4941543     520            621        PF00307.28   CH
  *LOXL2*        M570L       rs1063582     548            719        PF01186.14   Lysyl_oxidase
  *MCM4*         L650M       rs762679      447            769        PF00493.20   MCM
  *PLXND1*       H894R       rs2625962     891            976        PF01833.21   TIG
  *SLC17A9*      N228S       rs2427463       30           386        PF07690.13   MFS_1
  *SPHK1*        A34T        rs346803        16           137        PF00781.21   DAGK_cat
  *SPTBN2*       S825G       rs4930388     749            849        PF00435.18   Spectrin
  *SYNC*         R274Q       rs360042      187            456        PF00038.18   Filament
  *TNC*          Q539R       rs1757095     532            558        PF07974.10   EGF_2

SNP, single nucleotide polymorphism; Hmm acc, accession number of hmmer.

###### 

Significant GO and KEGG terms separately enriched for the upregulated and downregulated genes containing risk SNPs.

  A, Significant GO and KEGG terms enriched for the upregulated genes containing risk SNPs                                                                                                                                                                                                                                                                                                                                                      
  -------------------------------------------------------------------------------------------- ------------------------------------------------------------------ ------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------
  GO_BP                                                                                        GO:0001655\~urogenital system development                            6           *ACE, AR, BMP2, PGF, WFS1, ZBTB16*                                                                                                                                                                                                                              1.38E-03
  GO_BP                                                                                        GO:0055114\~oxidation reduction                                    13            *ALDH6A1, SORD, FOXRED2, OGDHL, AASS, CYP20A1, SOD3, IYD, ALDH1A1, ERO1LB, DIO2, BCO2, WWOX*                                                                                                                                                                    2.83E-03
  GO_BP                                                                                        GO:0031667\~response to nutrient levels                              7           *BMP2, GATM, MAP1LC3A, PPARG, LIPG, ADIPOR2, GHR*                                                                                                                                                                                                               3.56E-03
  GO_BP                                                                                        GO:0001822\~kidney development                                       5           *ACE, BMP2, PGF, WFS1, ZBTB16*                                                                                                                                                                                                                                  5.75E-03
  GO_BP                                                                                        GO:0043434\~response to peptide hormone stimulus                     6           *AR, EGR2, GATM, PPARG, FOXO1, GHR*                                                                                                                                                                                                                             5.91E-03
  GO_CC                                                                                        GO:0044421\~extracellular region part                              18            *TG, MATN2, BMP2, PODN, SORD, PGF, MMP15, CCL28, SOD3, TNFSF10, ACE, FBLN2, EMID1, NUCB2, LIPG, ANGPTL1, MFAP4, GHR*                                                                                                                                            5.34E-03
  GO_CC                                                                                        GO:0005794\~Golgi apparatus                                        16            *TG, SLC39A14, RAP1GAP, NCS1, ACACB, MAN1A1, SOD3, CSGALNACT1, AP1S3, SYNE1, EMID1, NUCB2, NDRG2, GRB14, WWOX, SMPD3*                                                                                                                                           1.14E-02
  GO_CC                                                                                        GO:0005925\~focal adhesion                                           5           *TNS3, PGM5, PRUNE, LAYN, LPP*                                                                                                                                                                                                                                  1.35E-02
  GO_CC                                                                                        GO:0005924\~cell-substrate adherens junction                         5           *TNS3, PGM5, PRUNE, LAYN, LPP*                                                                                                                                                                                                                                  1.53E-02
  GO_CC                                                                                        GO:0031985\~Golgi cisterna                                           3           *CSGALNACT1, NUCB2, SMPD3*                                                                                                                                                                                                                                      1.65E-02
  GO_MF                                                                                        GO:0042562\~hormone binding                                          4           *ALDH1A1, AR, ADIPOR2, GHR*                                                                                                                                                                                                                                     7.23E-03
  GO_MF                                                                                        GO:0005096\~GTPase activator activity                                7           *ALDH1A1, AGAP11, RAP1GAP, TBC1D4, OPHN1, RGS16, STARD13*                                                                                                                                                                                                       8.86E-03
  GO_MF                                                                                        GO:0008289\~lipid binding                                          10            *ALDH1A1, ALDH6A1, AR, MAP1LC3A, SDPR, OSBPL1A, FAAH, PPARG, CYTH3, PLEKHA2*                                                                                                                                                                                    1.06E-02
  GO_MF                                                                                        GO:0005543\~phospholipid binding                                     6           *MAP1LC3A, SDPR, OSBPL1A, FAAH, CYTH3, PLEKHA2*                                                                                                                                                                                                                 1.44E-02
  GO_MF                                                                                        GO:0050662\~coenzyme binding                                         6           *ALDH6A1, ERO1LB, SORD, OGDHL, FOXRED2, WWOX*                                                                                                                                                                                                                   1.57E-02
  Pathway                                                                                      hsa05200: Pathways in cancer                                         8           *AR, BMP2, PGF, PPARG, FOXO1, ZBTB16, TCF7L1, DAPK1*                                                                                                                                                                                                            1.28E-02
                                                                                                                                                                                                                                                                                                                                                                                                                                                
  B, Significant GO and KEGG terms enriched for the downregulated genes containing risk SNPs                                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                
  Category                                                                                     Term                                                               Gene number   Gene symbol                                                                                                                                                                                                                                                     P-value
  GO_BP                                                                                        GO:0022604\~regulation of cell morphogenesis                       20            *PALM, LST1, LZTS1, PTPRF, LIMK1, PLXNB2, CDH2, CDH4, TTL, TGFβ 2, NRCAM, FYN, TIAM1,MYH14, CDC42EP3, ARAP1, RASA1, MYH10, CDC42EP5, FN1*                                                                                                                       4.41E-09
  GO_BP                                                                                        GO:0007155\~cell adhesion                                          48            *MPZL3, NRP2, CLDN4, POSTN, CD151, CDSN, CTNNB1, NRCAM, PCDH1, WISP1, CD44*                                                                                                                                                                                     2.56E-08
  GO_BP                                                                                        GO:0022610\~biological adhesion                                    48            *MPZL3, NRP2, CLDN4, POSTN, CD151, CDSN, CTNNB1, NRCAM, PCDH1, WISP1, CD44*                                                                                                                                                                                     2.63E-08
  GO_BP                                                                                        GO:0043062\~extracellular structure organization                   20            *MPZL3, MYO6, ADAMTS14, LGALS3, SPOCK2, TNC, TGFβ R1, POSTN, CDH2, COL5A2, CTNNB1, ANXA2, TGFβ2, DVL1, NRCAM, AGT, COL1A2, AGRN, COL1A1, ADAMTS2*                                                                                                               1.63E-07
  GO_BP                                                                                        GO:0009611\~response to wounding                                   36            *DCBLD2, TNC, CLU, TLR2, CDH3, TNFRSF4, TGFβ2, CCL22, HRH1, NOD1, CD44, MAP3K1, SERPINE1, ITGB6, CFI, BLNK, RAB27A, FN1, NOX4, CIITA, NFKBIZ, LYN, OLR1, CFB, IL1RN, ANXA1, CHST2, NFAM1, CD55, BAX, VCAN, CTSB, PARP4, PROS1, ACVR1, MYH10*                    2.51E-06
  GO_MF                                                                                        GO:0005509\~calcium ion binding                                    55            *PXDN, LTBP1, S100A5, LDLR, ARSJ, EFHD2, PCDH1, GALNTL6, PADI2, ACTN1, NPTXR, CAPN12*                                                                                                                                                                           6.18E-07
  GO_MF                                                                                        GO:0030695\~GTPase regulator activity                              31            *TBC1D9, RASGEF1A, IQGAP1, PLEKHG2, RINL, TIAM1, RAPGEF5, RAP1GAP2, DOCK10, RASA1, RHOBTB3, NGEF, ARHGEF2, ABR, TNIK, PSD3, DOCK9, SIPA1L2, ARHGAP23, DOCK3, ANXA2, MAP4K4, CDC42BPG, RASGRF1, RGS4, RIN1, SYTL2, SH3BP1, LRRK2, SYTL1, ARAP1*                  2.83E-06
  GO_MF                                                                                        GO:0060589\~nucleoside-triphosphatase regulator activity           31            *TBC1D9, RASGEF1A, IQGAP1, PLEKHG2, RINL, TIAM1, RAPGEF5, RAP1GAP2, DOCK10, RASA1, RHOBTB3, NGEF, ARHGEF2, ABR, TNIK, PSD3, DOCK9, SIPA1L2, ARHGAP23, DOCK3, ANXA2, MAP4K4, CDC42BPG, RASGRF1, RGS4, RIN1, SYTL2, SH3BP1, LRRK2, SYTL1, ARAP1*                  4.39E-06
  GO_MF                                                                                        GO:0019899\~enzyme binding                                         34            *CDH2, IQGAP1, CTNNB1, MAP3K1, SERPINE1, CDK5RAP2, FAS, DOCK10, INSR, RASA1, CDC42EP5, RHOBTB3, FMNL2, ARHGEF2, LYN, TGFβR1, DOCK9, DOCK3, FLNA, DVL1, ANXA2, NRIP1, RFC5, MICALCL, CCND1, MAST2, CCND3, CCND2, IGF2R, SYTL2, PARP4, CACNA1C, SYTL1, ADAMTS4*   2.76E-05
  GO_MF                                                                                        GO:0008092\~cytoskeletal protein binding                             32          *SHROOM4, FXYD5, SDC4, KLHL2, NRCAM, FRMD3, CORO2A, FRMD5, MACF1, CDK5RAP2, MSN, CDC42EP3, RAB27A, FMNL2, ARHGEF2, MYO6, HTT, MYO1E, MYO1D, MYO1G, ACTN1, FLNA, ANXA2, FYN, ARPC5L, SPTBN2, FLII, MYH14, DST, FHOD1, LCP1, MYH10*                               7.90E-05
  GO_CC                                                                                        GO:0044459\~plasma membrane part                                   119           *MICB, SRCIN1, PTGS2, ATP1B3, GABRB2, TLR2, CTNNB1, NRCAM, ST3GAL5, CD44, KCNK5*                                                                                                                                                                                2.22E-11
  GO_CC                                                                                        GO:0005886\~plasma membrane                                        171           *MICB, ATP1B3, PTGS2, SRCIN1, GABRB2, TLR2, IQGAP1, CTNNB1, NRCAM, MCOLN3*                                                                                                                                                                                      2.42E-10
  GO_CC                                                                                        GO:0031012\~extracellular matrix                                     34          *ADAMTS17, LTBP1, ADAMTS14, SPOCK2, TNC, ADAMTSL5, POSTN, TGFβ2, TIMP1, LAMB3, CD44, FBN3, AGRN, FBN2, FGF1, LOXL1, FN1, LGALS3, COL13A1, PAPLN, SPARC, EMILIN2, COL5A2, ANXA2, ADAMTS9, BGN, NAV2, COL1A2, LAMC2, VCAN, COL1A1, DST, ADAMTS2, ADAMTS4*         3.48E-09
  GO_CC                                                                                        GO:0005578\~proteinaceous extracellular matrix                       32          *ADAMTS17, LTBP1, ADAMTS14, SPOCK2, TNC, ADAMTSL5, POSTN, TIMP1, LAMB3, FBN3, AGRN, FBN2, FGF1, LOXL1, FN1, LGALS3, COL13A1, PAPLN, SPARC, EMILIN2, COL5A2, ANXA2, ADAMTS9, BGN, NAV2, COL1A2, LAMC2, VCAN, COL1A1, DST, ADAMTS2, ADAMTS4*                      7.79E-09
  GO_CC                                                                                        GO:0005887\~integral to plasma membrane                              71          *MICB, LDLR, CLDN4, SLC20A1, ATP1B3, CORIN, GABRB2, TLR2, GABBR2, CD151, SDC4*                                                                                                                                                                                  2.00E-08
  Pathway                                                                                      hsa04514: Cell adhesion molecules (CAMs)                             19          *CLDN16, ICAM1, CLDN4, PTPRF, CDH2, HLA-B, CDH3, SDC4, CDH4, NRCAM, ITGA9, ITGB8, CD58, CLDN1, HLA-DPA1, VCAN, CNTNAP1, HLA-DOA, HLA-DRA*                                                                                                                       1.16E-06
  Pathway                                                                                      hsa04512: ECM-receptor interaction                                   15          *TNC, ITGA11, ITGA3, SDC4, COL5A2, ITGA9, LAMB3, CD44, ITGB8, ITGB6, COL1A2, LAMC2, AGRN, COL1A1, FN1*                                                                                                                                                          1.68E-06
  Pathway                                                                                      hsa04510: Focal adhesion                                             22          *TNC, MET, ITGA11, ACTN1, ITGA3, COL5A2, FLNA, CTNNB1, ITGA9, LAMB3, CCND1, CCND3, CCND2, ITGB8, RASGRF1, FYN, ITGB6, COL1A2, LAMC2, COL1A1, SHC3, FN1*                                                                                                         1.17E-05
  Pathway                                                                                      hsa05412: Arrhythmogenic right ventricular cardiomyopathy (ARVC)     12          *ITGA9, DSG2, PKP2, ITGB8, ITGB6, ITGA11, CACNB1, ACTN1, ITGA3, CDH2, CACNA1C, CTNNB1*                                                                                                                                                                          8.78E-05
  Pathway                                                                                      hsa04115: p53 signaling pathway                                      11          *CCNE2, CCND1, TNFRSF10B, CCND3, CCND2, ZMAT3, BAX, SERPINE1, DDB2, FAS, PERP*                                                                                                                                                                                  

GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; SNP, single nucleotides polymorphism; BP, biological process; CC, cellular component; MF, molecular function.

###### 

Protein-protein interaction pairs containing the non-synonymous risk single nucleotide polymorphism loci in the interaction domains.

  Protein-1   Protein-2   Domain-1   Domain-2
  ----------- ----------- ---------- ----------
  TNC         FN1         PF00041    PF00041
  FN1         COL1A1      PF00041    PF01391
  FN1         COL1A2      PF00041    PF01391
  COL1A1      COL7A1      PF01391    PF01391
  FN1         COL7A1      PF00041    PF01391
  FN1         COL13A1     PF00041    PF01391
  MCM4        MCM2        PF00493    PF00493

TNC, tenascin C; FN1, fibronectin 1; MCM, minichromosome maintenance; COL, collagen type.
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